Charles Schwab
HLVX

Charles Schwab’s HilleVax HLVX Stock Holding History

Charles Schwab’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75,937
Closed -$110K – 3526
2025
Q1 		$110K Buy
75,937
+341
+0.5% +$630 ﹤0.01% 3331
2024
Q4 		$156K Hold
75,596
– – ﹤0.01% 3353
2024
Q3 		$133K Sell
75,596
-149,271
-66% -$383K ﹤0.01% 3366
2024
Q2 		$3.25M Buy
224,867
+18,601
+9% +$256K ﹤0.01% 2533
2024
Q1 		$3.43M Sell
206,266
-2,507
-1% -$40.1K ﹤0.01% 2427
2023
Q4 		$3.35M Buy
208,773
+63,125
+43% +$839K ﹤0.01% 2472
2023
Q3 		$1.96M Buy
145,648
+33,508
+30% +$472K ﹤0.01% 2610
2023
Q2 		$1.93M Buy
112,140
+9,299
+9% +$144K ﹤0.01% 2559
2023
Q1 		$1.7M Sell
102,841
-259
-0.3% -$4.14K ﹤0.01% 2568
2022
Q4 		$1.72M Buy
103,100
+11,278
+12% +$204K ﹤0.01% 2613
2022
Q3 		$1.57M Buy
91,822
+1,157
+1% +$16.8K ﹤0.01% 2651
2022
Q2 		$991K Buy
+90,665
New +$1.08M ﹤0.01% 2802

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Charles Schwab's HLVX Position: Q2 2025 in Review

Charles Schwab sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 75,937 shares — an estimated $110K sold.

Charles Schwab first reported a position in HLVX in Q2 2022 and held it in 12 quarters. The position peaked at $3.43M in Q1 2024. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • Charles Schwab reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 75,937 HilleVax shares in Q2 2025, an estimated $110K.
  • Charles Schwab first reported a position in HilleVax in Q2 2022 and held it in 12 quarters.
  • Charles Schwab's HilleVax position peaked at $3.43M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.